PHARMING GROUP NV (PHARM.AS) Fundamental Analysis & Valuation

AMS:PHARM • NL0010391025

Current stock price

1.417 EUR
-0.01 (-0.49%)
Last:

This PHARM.AS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. PHARM.AS Profitability Analysis

1.1 Basic Checks

  • In the past year PHARM has reported negative net income.
  • In the past year PHARM had a positive cash flow from operations.
  • In multiple years PHARM reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: PHARM reported negative operating cash flow in multiple years.
PHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFPHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M

1.2 Ratios

  • PHARM's Return On Assets of 0.57% is fine compared to the rest of the industry. PHARM outperforms 66.67% of its industry peers.
  • Looking at the Return On Equity, with a value of 1.03%, PHARM is in the better half of the industry, outperforming 72.22% of the companies in the same industry.
  • PHARM's Return On Invested Capital of 7.06% is fine compared to the rest of the industry. PHARM outperforms 79.17% of its industry peers.
Industry RankSector Rank
ROA 0.57%
ROE 1.03%
ROIC 7.06%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
PHARM.AS Yearly ROA, ROE, ROICPHARM.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • PHARM's Profit Margin of 0.76% is fine compared to the rest of the industry. PHARM outperforms 68.06% of its industry peers.
  • PHARM's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 9.61%, PHARM is in the better half of the industry, outperforming 76.39% of the companies in the same industry.
  • PHARM's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 87.90%, PHARM belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
  • PHARM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 9.61%
PM (TTM) 0.76%
GM 87.9%
OM growth 3Y19.98%
OM growth 5Y-24.69%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
PHARM.AS Yearly Profit, Operating, Gross MarginsPHARM.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PHARM.AS Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHARM is destroying value.
  • Compared to 1 year ago, PHARM has more shares outstanding
  • PHARM has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for PHARM has been reduced compared to a year ago.
PHARM.AS Yearly Shares OutstandingPHARM.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
PHARM.AS Yearly Total Debt VS Total AssetsPHARM.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • PHARM has an Altman-Z score of 3.93. This indicates that PHARM is financially healthy and has little risk of bankruptcy at the moment.
  • PHARM's Altman-Z score of 3.93 is fine compared to the rest of the industry. PHARM outperforms 66.67% of its industry peers.
  • The Debt to FCF ratio of PHARM is 2.15, which is a good value as it means it would take PHARM, 2.15 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 2.15, PHARM belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
  • A Debt/Equity ratio of 0.39 indicates that PHARM is not too dependend on debt financing.
  • PHARM has a Debt to Equity ratio of 0.39. This is comparable to the rest of the industry: PHARM outperforms 55.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Altman-Z 3.93
ROIC/WACC1
WACC7.09%
PHARM.AS Yearly LT Debt VS Equity VS FCFPHARM.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • PHARM has a Current Ratio of 2.59. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
  • PHARM's Current ratio of 2.59 is in line compared to the rest of the industry. PHARM outperforms 55.56% of its industry peers.
  • PHARM has a Quick Ratio of 2.03. This indicates that PHARM is financially healthy and has no problem in meeting its short term obligations.
  • PHARM's Quick ratio of 2.03 is in line compared to the rest of the industry. PHARM outperforms 51.39% of its industry peers.
Industry RankSector Rank
Current Ratio 2.59
Quick Ratio 2.03
PHARM.AS Yearly Current Assets VS Current LiabilitesPHARM.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. PHARM.AS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 111.11% over the past year.
  • PHARM shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -48.41% yearly.
  • The Revenue has grown by 26.56% in the past year. This is a very strong growth!
  • Measured over the past years, PHARM shows a quite strong growth in Revenue. The Revenue has been growing by 12.13% on average per year.
EPS 1Y (TTM)111.11%
EPS 3Y-41.82%
EPS 5Y-48.41%
EPS Q2Q%60%
Revenue 1Y (TTM)26.56%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%

3.2 Future

  • Based on estimates for the next years, PHARM will show a very strong growth in Earnings Per Share. The EPS will grow by 157.07% on average per year.
  • The Revenue is expected to grow by 16.27% on average over the next years. This is quite good.
EPS Next Y1671.6%
EPS Next 2Y376.03%
EPS Next 3Y187.89%
EPS Next 5Y157.07%
Revenue Next Year8.86%
Revenue Next 2Y5.64%
Revenue Next 3Y0.12%
Revenue Next 5Y16.27%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PHARM.AS Yearly Revenue VS EstimatesPHARM.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
PHARM.AS Yearly EPS VS EstimatesPHARM.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

Find the best growth stocksShow best growing peers

5

4. PHARM.AS Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Forward Earnings ratio of 46.99, the valuation of PHARM can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PHARM indicates a somewhat cheap valuation: PHARM is cheaper than 76.39% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of PHARM to the average of the S&P500 Index (21.99), we can say PHARM is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 46.99
PHARM.AS Price Earnings VS Forward Price EarningsPHARM.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • 73.61% of the companies in the same industry are more expensive than PHARM, based on the Enterprise Value to EBITDA ratio.
  • PHARM's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PHARM is cheaper than 84.72% of the companies in the same industry.
Industry RankSector Rank
P/FCF 21.79
EV/EBITDA 22.9
PHARM.AS Per share dataPHARM.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PHARM's earnings are expected to grow with 187.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y376.03%
EPS Next 3Y187.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHARM.AS Dividend Analysis

5.1 Amount

  • No dividends for PHARM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARM.AS Fundamentals: All Metrics, Ratios and Statistics

PHARMING GROUP NV

AMS:PHARM (4/28/2026, 7:00:00 PM)

1.417

-0.01 (-0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-07
Inst Owners21.67%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap1.00B
Revenue(TTM)376.13M
Net Income(TTM)2.85M
Analysts88.57
Price Target2.26 (59.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)532.06%
Min EPS beat(2)-6.76%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)286.26%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)81.54%
EPS beat(12)5
Avg EPS beat(12)48.19%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.68%
Max Revenue beat(2)1.11%
Revenue beat(4)3
Avg Revenue beat(4)5.37%
Min Revenue beat(4)-1.68%
Max Revenue beat(4)13.37%
Revenue beat(8)4
Avg Revenue beat(8)0.36%
Revenue beat(12)7
Avg Revenue beat(12)0.29%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.91%
PT rev (3m)4.86%
EPS NQ rev (1m)333.33%
EPS NQ rev (3m)-78.33%
EPS NY rev (1m)-10.42%
EPS NY rev (3m)35.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 46.99
P/S 3.13
P/FCF 21.79
P/OCF 21.49
P/B 4.24
P/tB 8.31
EV/EBITDA 22.9
EPS(TTM)0
EYN/A
EPS(NY)0.03
Fwd EY2.13%
FCF(TTM)0.07
FCFY4.59%
OCF(TTM)0.07
OCFY4.65%
SpS0.45
BVpS0.33
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 0.57%
ROE 1.03%
ROCE 9.41%
ROIC 7.06%
ROICexc 13.22%
ROICexgc 38.98%
OM 9.61%
PM (TTM) 0.76%
GM 87.9%
FCFM 14.34%
ROA(3y)-1.56%
ROA(5y)0.51%
ROE(3y)-3.05%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y56.06%
ROICexgc growth 5Y-23.52%
ROICexc growth 3Y34.74%
ROICexc growth 5Y-22.16%
OM growth 3Y19.98%
OM growth 5Y-24.69%
PM growth 3Y-51.51%
PM growth 5Y-46.8%
GM growth 3Y-1.31%
GM growth 5Y-0.23%
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF 2.15
Debt/EBITDA 2.26
Cap/Depr 6.73%
Cap/Sales 0.2%
Interest Coverage 5.83
Cash Conversion 115.52%
Profit Quality 1892.42%
Current Ratio 2.59
Quick Ratio 2.03
Altman-Z 3.93
F-Score6
WACC7.09%
ROIC/WACC1
Cap/Depr(3y)6.96%
Cap/Depr(5y)24.22%
Cap/Sales(3y)0.36%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)111.11%
EPS 3Y-41.82%
EPS 5Y-48.41%
EPS Q2Q%60%
EPS Next Y1671.6%
EPS Next 2Y376.03%
EPS Next 3Y187.89%
EPS Next 5Y157.07%
Revenue 1Y (TTM)26.56%
Revenue growth 3Y22.3%
Revenue growth 5Y12.13%
Sales Q2Q%14.96%
Revenue Next Year8.86%
Revenue Next 2Y5.64%
Revenue Next 3Y0.12%
Revenue Next 5Y16.27%
EBIT growth 1Y519.14%
EBIT growth 3Y46.74%
EBIT growth 5Y-15.55%
EBIT Next Year4.35%
EBIT Next 3Y34.62%
EBIT Next 5Y57.73%
FCF growth 1Y2182.32%
FCF growth 3Y38.11%
FCF growth 5Y-4.61%
OCF growth 1Y3147.8%
OCF growth 3Y34.55%
OCF growth 5Y-8.14%

PHARMING GROUP NV / PHARM.AS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PHARMING GROUP NV (PHARM.AS) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PHARM.AS.


What is the valuation status for PHARM stock?

ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHARM.AS). This can be considered as Fairly Valued.


What is the profitability of PHARM stock?

PHARMING GROUP NV (PHARM.AS) has a profitability rating of 4 / 10.


What is the financial health of PHARMING GROUP NV (PHARM.AS) stock?

The financial health rating of PHARMING GROUP NV (PHARM.AS) is 7 / 10.